Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ENSG00000228286 encodes the Docking protein 1, 62kDa (downstream of tyrosine kinase 1) pseudogene in Homo sapiens[1][3]. It is annotated as a pseudogene, meaning it is derived from the protein-coding gene DOK1 but has accumulated mutations that prevent it from producing a functional protein[1][3][4]. Pseudogenes typically lack protein-coding capability and, therefore, are not considered therapeutic targets and have no known roles in drug interactions, diagnostics, or disease management[4]. There is no current evidence suggesting that this specific pseudogene has regulatory or protein-coding function, nor is it known to be involved in any specific biological process, disease, or considered for biomarker use[1][3][4]. Thus, it is not a valid target for therapeutic intervention, and its listing as a target is considered incorrect[1][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Docking protein 1, 62kDa (downstream of tyrosine kinase 1) pseudogene (DOK1 pseudogene).